Recent research have centered on the intersection of GLP|GIP|glucagon receptor agonist therapies and DA signaling. While GCGR stimulators are widely employed for addressing type 2 T2DM, their potential consequences on motivation circuits, specifically governed by dopaminergic networks, are attrac